Advertisement

Rapid Relief of Rhinitis with R112

Novel Therapy May Impact a Congested Market
Emerging Technologies
  • 4 Downloads

Executive summary

Allergic rhinitis is a chronic inflammatory disorder caused by ‘overreaction’ of an individual’s immune system to an environmental substance (allergen). The four main symptoms are sneezing, nasal congestion, rhinorrhea (runny nose) and itching in the eyes, ears, nose and throat, reflecting the underlying inflammation of mucosal surfaces. Affecting around 20% of the US population, allergic rhinitis has a significant negative effect on patient quality of life and is associated with an annual economic burden of approximately $US5.3 billion. Although a range of pharmacological therapies is available for allergic rhinitis, intranasal corticosteroids and oral antihistamines dominate the market.

A major unmet need in allergic rhinitis therapy is management of patients unable to achieve adequate control of symptoms with available drugs. Therefore, interest is growing in therapies with novel mechanisms of action. One such candidate is R112 from Rigel Pharmaceuticals, a...

Keywords

Allergic Rhinitis Montelukast Triamcinolone Acetonide Seasonal Allergic Rhinitis Desloratadine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Reference

  1. 1.
    Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005; 115 (4): 791–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Personalised recommendations